




US 20210189001A1

(19) **United States**(12) **Patent Application Publication**
Wickman et al.(10) **Pub. No.: US 2021/0189001 A1**(43) **Pub. Date: Jun. 24, 2021**(54) **METHODS OF USING BISPECIFIC
ANTIGEN-BINDING CONSTRUCTS
TARGETING HER2**(71) Applicant: **Zymeworks Inc.**, Vancouver (CA)(72) Inventors: **Grant Raymond Wickman**, Vancouver
(CA); **Gordon Yiu Kon Ng**, Vancouver
(CA); **Nina E. Weissner**, Delta (CA)(21) Appl. No.: **17/033,441**(22) Filed: **Sep. 25, 2020****Related U.S. Application Data**(63) Continuation of application No. 15/526,888, filed on
May 15, 2017, now abandoned, filed as application
No. PCT/CA2015/051238 on Nov. 26, 2015.(60) Provisional application No. 62/166,844, filed on May
27, 2015.**Publication Classification**(51) **Int. Cl.****C07K 16/32** (2006.01)**A61K 47/68** (2006.01)**A61K 39/395** (2006.01)**C07K 16/28** (2006.01)(52) **U.S. Cl.**CPC **C07K 16/32** (2013.01); **A61K 2039/505**
(2013.01); **A61K 47/6855** (2017.08); **A61K**
47/6869 (2017.08); **A61K 47/6879** (2017.08);
A61K 39/395 (2013.01); **C07K 16/28**
(2013.01); **C07K 2317/31** (2013.01); **C07K**
2317/732 (2013.01); **C07K 2317/76** (2013.01);
C07K 2317/92 (2013.01); **C07K 2317/94**
(2013.01); **C07K 2317/24** (2013.01); **C07K**
2317/41 (2013.01); **C07K 2317/522** (2013.01);
C07K 2317/526 (2013.01); **C07K 2317/77**
(2013.01); **C07K 2317/64** (2013.01); **C07K**
2317/73 (2013.01); **C07K 2317/72** (2013.01);
A61K 47/6803 (2017.08)

(57)

ABSTRACT

Described herein methods of using antigen-binding constructs to treat HER2+ tumors in a subject such as breast, lung, or head and neck tumors. In some aspects, the tumor volume in the subject after receiving at least seven doses of the antigen binding construct is less than the tumor volume of a control subject receiving an equivalent amount of trastuzumab. In some aspects, the survival of the subject receiving the antigen binding construct is increased as compared to a control subject receiving an equivalent amount of a non-specific control antibody or as compared to a control subject not receiving treatment.

Specification includes a Sequence Listing.**A****B**